Morgan Stanley
AURA icon

Morgan Stanley’s Aura Biosciences AURA Stock Holding History

Morgan Stanley’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.24M Sell
174,692
-49,349
-22% -$353K ﹤0.01% 5111
2026
Q1 		$1.5M Buy
224,041
+5,634
+3% +$32.3K ﹤0.01% 4935
2025
Q4 		$1.19M Buy
218,407
+39,902
+22% +$237K ﹤0.01% 5091
2025
Q3 		$1.1M Buy
178,505
+28,217
+19% +$185K ﹤0.01% 5125
2025
Q2 		$941K Buy
150,288
+50,841
+51% +$297K ﹤0.01% 5126
2025
Q1 		$583K Sell
99,447
-63,582
-39% -$481K ﹤0.01% 5263
2024
Q4 		$1.34M Sell
163,029
-20,965
-11% -$197K ﹤0.01% 4935
2024
Q3 		$1.64M Buy
183,994
+101,154
+122% +$867K ﹤0.01% 4765
2024
Q2 		$626K Sell
82,840
-4,016
-5% -$29.4K ﹤0.01% 5187
2024
Q1 		$682K Buy
86,856
+4,089
+5% +$33.9K ﹤0.01% 5169
2023
Q4 		$733K Buy
82,767
+61,683
+293% +$522K ﹤0.01% 5113
2023
Q3 		$189K Sell
21,084
-59,581
-74% -$641K ﹤0.01% 5602
2023
Q2 		$996K Buy
80,665
+8,072
+11% +$86.3K ﹤0.01% 4833
2023
Q1 		$674K Buy
72,593
+7,990
+12% +$83K ﹤0.01% 5084
2022
Q4 		$678K Buy
64,603
+9,451
+17% +$120K ﹤0.01% 5073
2022
Q3 		$1M Buy
55,152
+613
+1% +$9.28K ﹤0.01% 4878
2022
Q2 		$772K Buy
54,539
+53,430
+4,818% +$884K ﹤0.01% 5183
2022
Q1 		$24K Buy
1,109
+575
+108% +$11K ﹤0.01% 7064
2021
Q4 		$9K Buy
+534
New +$9.54K ﹤0.01% 7491

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Morgan Stanley's AURA Position: Q2 2026 in Review

Morgan Stanley reduced its Aura Biosciences (AURA) stake by 22% in Q2 2026, selling an estimated $353K and leaving 174,692 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #5111.

Morgan Stanley first reported a position in AURA in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.64M in Q3 2024. 146 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Morgan Stanley held 174,692 shares of Aura Biosciences worth $1.24M as of Q2 2026.
  • Morgan Stanley sold 49,349 Aura Biosciences shares in Q2 2026, an estimated $353K.
  • Aura Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5111 holding.
  • Morgan Stanley first reported a position in Aura Biosciences in Q4 2021 and has held it in 19 quarters since.
  • Morgan Stanley's Aura Biosciences position peaked at $1.64M in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.